Literature DB >> 31865247

IgA plasma cell neoplasms are characterized by poorer long-term survival and increased genomic complexity compared to IgG neoplasms.

Gabriel K Habermehl1, Megan O Nakashima1, Claudiu V Cotta2.   

Abstract

The characteristics of the IgA plasma cell neoplasms are not clearly reported in the literature. The main goal of this study is to examine IgA plasma cell neoplasms (PCN) and to compare them to IgG lesions. After at least 5 years from the identification of an M protein, 98 cases were selected, the presentation and clinical evolution of 45 IgA neoplasms were compared to 43 cases of IgG gammopathies. The classification at presentation as monoclonal gammopathy of undermined significance (MGUS)-22 of 45 IgA and 20 of 43 IgG (49 vs 46%), plasma cell myeloma (PCM)-22 of 45 IgA and 22 of 43 IgG (49 vs 51%) and smoldering PCM (SPCM)-1 each (2% for both) was essentially identical. No solitary plasmacytomas were identified. At presentation, IgA patients were younger (66.5 ± 11.3 vs. 69.2 ± 10.7 years), less likely to have bone lesions (12/45 vs 18/43, p < 0.14) or immunoparesis (51% vs. 63%), differences statistically insignificant. Cases with normal fluorescence in-situ hybridization (FISH) results, 27% for IgA vs 61% for IgG (p < 0.037) were statistically different. The IgA patients had worse survival (80 vs 108 months median IgA vs IgG, p < 0.013), difference not detectable in the first 5 years, but substantial after 10. In conclusion, poorer long-term survival and increased genomic complexity by FISH are characteristics of IgA PCNs.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Genetic complexity; IgA; Myeloma; Plasma cell; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 31865247     DOI: 10.1016/j.anndiagpath.2019.151449

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  1 in total

1.  Retrospective evaluation of the use of the International Myeloma Working Group response criteria in dogs with secretory multiple myeloma.

Authors:  A Russell Moore; Adam Harris; Christina Jeffries; Paul R Avery; Kate Vickery
Journal:  J Vet Intern Med       Date:  2020-11-20       Impact factor: 3.175

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.